Mostrar el registro sencillo del ítem

dc.contributor.authorCillero Pastor, Berta 
dc.contributor.authorRego-Pérez, Ignacio
dc.contributor.authorOREIRO VILLAR, NATIVIDAD 
dc.contributor.authorFernandez Lopez, Carlos
dc.contributor.authorBLANCO GARCIA, FRANCISCO JAVIER 
dc.date.accessioned2017-06-07T06:56:57Z
dc.date.available2017-06-07T06:56:57Z
dc.date.issued2013
dc.identifier.issn1471-2474
dc.identifier.urihttp://hdl.handle.net/20.500.11940/889
dc.description.abstractBackground: Mitochondrion has an important role in the osteoarthritis (OA) pathology. We have previously demonstrated that the alteration of the mitochondrial respiratory chain (MRC) contributes to the inflammatory response of the chondrocyte. However its implication in the process of cartilage destruction is not well understood yet. In this study we have investigated the relationship between the MRC dysfunction and the regulation of metalloproteases (MMPs) in human normal chondrocytes in culture. Methods: Human normal chondrocytes were isolated from human knees obtained form autopsies of donors without previous history of rheumatic disease. Rotenone, 3-Nitropropionic acid (NPA), Antimycin A (AA), Sodium azide and Oligomycin were used to inhibit the activity of the mitochondrial complexes I, II, III, IV and V respectively. The mRNA expression of MMPs -1, -3 and -13 was studied by real time PCR. The intracellular presence of MMP proteins was evaluated by western blot. The liberation of these proteins to the extracellular media was evaluated by ELISA. The presence of proteoglycans in tissue was performed with tolouidin blue and safranin/fast green. Immunohistochemistry was used for evaluating MMPs on tissue. Results: Firstly, cells were treated with the inhibitors of the MRC for 24 hours and mRNA expression was evaluated. An up regulation of MMP-1 and -3 mRNA levels was observed after the treatment with Oligomycin 5 and 100 μg/ml (inhibitor of the complex V) for 24 hours. MMP-13 mRNA expression was reduced after the incubation with AA 20 and 60 μg/ml (inhibitor of complex III) and Oligomycin. Results were validated at protein level observing an increase in the intracellular levels of MMP-1 and -3 after Oligomycin 25 μg/ml stimulation [(15.20±8.46 and 4.59±1.83 vs. basal=1, respectively (n=4; *P<0.05)]. However, AA and Oligomycin reduced the intracellular levels of the MMP-13 protein (0.70±0.16 and 0.3±0.24, respectively vs. basal=1). In order to know whether the MRC dysfunction had an effect on the liberation of MMPs, their levels were evaluated in the supernatants. After 36 hours of stimulation, values were: MMP-1=18.06±10.35 with Oligomycin 25 μg/ml vs. basal=1, and MMP-3=8.49±4.32 with Oligomycin 5 μg/ml vs. basal=1 (n=5; *P<0.05). MMP-13 levels in the supernatants were reduced after AA 60 μg/ml treatment (0.50±0.13 vs. basal=1) and Oligomycin 25 μg/ml (0.41±0.14 vs. basal=1); (n=5; *P<0.05). The treatment of explants with Oligomycin, showed an increase in the positivity of MMP-1 and -3. Explants stimulated with AA or Oligomycin revealed a decrease in MMP-13 expression. Proteoglycan staining demonstrated a reduction of proteoglycan levels in the tissues treated with Oligomycin. Conclusions: These results reveal that MRC dysfunction modulates the MMPs expression in human normal chondrocytes demonstrating its role in the regulation of the cartilage destruction.
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshCartilage, Articular
dc.subject.meshCells, Cultured
dc.subject.meshChondrocytes
dc.subject.meshMetalloproteases
dc.subject.meshMitochondrial Diseases
dc.titleMitochondrial respiratory chain dysfunction modulates metalloproteases -1, -3 and -13 in human normal chondrocytes in culture
dc.typeArtigoes
dc.authorsophosCillero-Pastor, B.
dc.authorsophosRego-Pérez, I.
dc.authorsophosOreiro, N.
dc.authorsophosFernandez-Lopez, C.
dc.authorsophosBlanco, F. J.
dc.identifier.doi10.1186/1471-2474-14-235
dc.identifier.pmid23937653
dc.identifier.sophos11557
dc.journal.titleBMC MUSCULOSKELETAL DISORDERS
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario A Coruña::Reumatoloxía
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña::INIBIC.- Instituto de Investigación Biomédica
dc.rights.accessRightsopenAccess
dc.subject.decsCélulas Cultivadas
dc.subject.decsCartílago Articular
dc.subject.decsCondrocitos
dc.subject.decsMetaloproteasas
dc.subject.decsEnfermedades Mitocondriales
dc.typesophosArtículo Original
dc.volume.number14


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional